SABCS 2022 | First-line camizestrant for ER+/HER2- advanced breast cancer

Mafalda Oliveira, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, talks on the exploration of camizestrant in in metastatic ER-positive, HER2-negative (ER+/HER2-) breast cancer. . Currently, camizestrant is being investigated in advanced ER-positive, HER2-negative ER+/HER2- breast cancer in the first-line setting in two clinical trials. Phase III SERENA-4 (NCT04711252) trial investigating camizestrant plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. The Phase III SERENA-6 (NCT04964934) trial is exploring camizestrant compared with aromatase inhibitors when given in combination with palbociclib or abemaciclib in patients with HR+/HER2- metastatic breast cancer with detectable ESR1 mutations who have not experienced disease progression on first-line therapy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved